Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_3
1
50%
Ph phase_2
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Completed(1)

Detailed Status

Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (50.0%)
Phase 31 (50.0%)

Trials by Status

recruiting150%
completed150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingphase_2

Clinical Trial With MBK-01, Intestinal Microbiota Capsules, for the Treatment of Patients With Recurrent Diverticulitis

NCT06687382
completedphase_3

Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin

NCT05201079

Clinical Trials (2)

Showing 2 of 2 trials
NCT06687382Phase 2

Clinical Trial With MBK-01, Intestinal Microbiota Capsules, for the Treatment of Patients With Recurrent Diverticulitis

Recruiting
NCT05201079Phase 3

Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin

Completed

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2